drugset / Trial / NCT06313567
Metronomic Capecitabine in Stage III Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether treatment with metronomic capecitabine will improve the survival of gastric cancer patients with stage III who had received standard treatment.
Timeline
- Start
- 2024-03-10
- Primary completion
- 2029-03-10
- Completion
- 2029-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 500 mg/m2 | — |